State of the art paper Asthma: beyond corticosteroid treatment

Marandi, Yasser; Farahi, Neda; Hashjin, Goudarz Sadeghi

doi:10.5114/aoms.2013.33179

Cited by 19 publications

(14 citation statements)

References 44 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of patients’ compliance may also be responsible for unsuccessful treatment in this group. It should be emphasized, however, that limited treatment efficacy of NAEB (or even asthma) has also been reported by other authors [36, 37]. In an observational study by Berry et al ., cough and induced sputum eosinophilia persisted in some patients with NAEB despite treatment with inhaled corticosteroids.…”

Section: Discussionmentioning

confidence: 78%

Chronic cough – assessment of treatment efficacy based on two questionnaires

Dąbrowska¹,

Grabczak²,

Arcimowicz³

et al. 2014

aoms

View full text Add to dashboard Cite

IntroductionEfficacy of chronic cough treatment is ambiguous. The aim of the study was to analyze chronic cough alleviation after specific treatment and the relationship between cough etiology and treatment efficacy.Material and methodsA stepwise diagnostic approach was used to diagnose cough etiology in non-smoking adults with chronic cough. In all patients specific treatment was applied. Two different questionnaires – a visual analog scale and a 5-degree scale – were used to assess cough severity before and after 4-6 months of treatment.ResultsA significant correlation between pre-treatment and post-treatment results of both questionnaires was found (Spearman coefficient 0.43, p = 0.0003 and 0.73, p < 0.0001, respectively). Baseline questionnaire analysis revealed no differences in cough severity between patients with different cough causes or multiple cough causes. Although specific treatment resulted in a significant decrease of cough severity in the entire group, only partial improvement was noted. According to the visual analogue scale, a decrease of cough severity by at least 50% was achieved only in 54.4% of patients (37/68). Similarly, satisfactory improvement was noted in only 54.4% (37/68) of patients when using the 5-point scale. There were three sub-groups of patients, in whom no relevant decrease of cough severity was observed despite treatment: patients with 1. three coexisting cough causes, 2. non-asthmatic eosinophilic bronchitis, and 3. chronic idiopathic cough.ConclusionsCough severity does not depend on its etiology. Efficacy of chronic cough treatment in non-smoking patients is only moderate.

show abstract

Section: Discussionmentioning

confidence: 78%

Chronic cough – assessment of treatment efficacy based on two questionnaires

Dąbrowska¹,

Grabczak²,

Arcimowicz³

et al. 2014

aoms

View full text Add to dashboard Cite

show abstract

“…CASI identified 12 genomic regions defined by the positions of 12 genes with evidence of statistical interactions between sets of SNPs and sets of methylated CpGs with respect to asthma risk. Of these 12 genes, 3 have previously been implicated in asthma risk or underlying biological pathways related to pathology of the disease, i.e., PF4 [39], ATF3 [40,41], and TPRA1 [42]. Three genomic regions not previously implicated in asthma, LOC101928523, SCARNA18, and LHX6, contained the most statistically significant pairwise interactions between the considered individual SNPs and CpGs.…”

Section: Discussionmentioning

confidence: 99%

Genetic-Epigenetic Interactions in Asthma Revealed by a Genome-Wide Gene-Centric Search

et al. 2018

View full text Add to dashboard Cite

Objectives: There is evidence to suggest that asthma pathogenesis is affected by both genetic and epigenetic variation independently, and there is some evidence to suggest that genetic-epigenetic interactions affect risk of asthma. However, little research has been done to identify such interactions on a genome-wide scale. The aim of this studies was to identify genes with genetic-epigenetic interactions associated with asthma. Methods: Using asthma case-control data, we applied a novel nonparametric gene-centric approach to test for interactions between multiple SNPs and CpG sites simultaneously in the vicinities of 18,178 genes across the genome. Results: Twelve genes, PF4, ATF3, TPRA1, HOPX, SCARNA18, STC1, OR10K1, UPK1B, LOC101928523, LHX6, CHMP4B, and LANCL1, exhibited statistically significant SNP-CpG interactions (false discovery rate = 0.05). Of these, three have previously been implicated in asthma risk (PF4, ATF3, and TPRA1). Follow-up analysis revealed statistically significant pairwise SNP-CpG interactions for several of these genes, including SCARNA18, LHX6, and LOC101928523 (p = 1.33E–04, 8.21E–04, 1.11E–03, respectively). Conclusions: Joint effects of genetic and epigenetic variation may play an important role in asthma pathogenesis. Statistical methods that simultaneously account for multiple variations across chromosomal regions may be needed to detect these types of effects on a genome-wide scale.

show abstract

“…It is recognized that airway inflammation is pivotal in asthma pathogenesis and it is characterized by activation of mast cells, infiltration of eosinophils and increases in the number of activated T helper (Th)2 cells, which mediate allergic inflammation through the secretion of an array of cytokines [1,12]. Inhaled corticosteroids block late-phase reactions to allergens, reduce airway hyperresponsiveness and inhibit inflammatory cell migration and activation [9].…”

Section: Use Of Corticosteroids In Asthmamentioning

confidence: 99%

Novel glucocorticoid receptor agonists in the treatment of asthma

Cazzola

Coppola

Rogliani

et al. 2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Several agents have been synthesized, but few have been tested in experimental models of asthma. Furthermore, only three (BI-54903, GW870086X and AZD5423) have entered clinical development, although the development of at least one of them (BI-54903) was discontinued. The reason for the limited success so far obtained is that the model of transactivation versus transrepression is a too simplistic representation of GR activity. It is difficult to uncouple the therapeutic and harmful effects mediated by GR, but some useful information that might change the current perspective is appearing in the literature. The generation of gene expression 'fingerprints' produced by different GR agonists in target and off-target human tissues could be useful in identifying drug candidates with an improved therapeutic ratio.

show abstract

State of the art paper Asthma: beyond corticosteroid treatment

Cited by 19 publications

References 44 publications

Chronic cough – assessment of treatment efficacy based on two questionnaires

Chronic cough – assessment of treatment efficacy based on two questionnaires

Genetic-Epigenetic Interactions in Asthma Revealed by a Genome-Wide Gene-Centric Search

Novel glucocorticoid receptor agonists in the treatment of asthma

Contact Info

Product

Resources

About